BACKGROUND:Bipolar patients are at risk for relapses of their illness even when undergoing optimal pharmacotherapy. This study was performed to determine whether combining family-focused therapy (FFT) with pharmacotherapy during a postepisode interval enhances patients' mood stability during maintenance treatment. METHODS: In a randomized controlled trial, 101 bipolar patients were assigned to FFT and pharmacotherapy or a less intensive crisis management (CM) intervention and pharmacotherapy. Outcome assessments were conducted every 3 to 6 months for 2 years. Participants (mean +/- SD age, 35.6 +/- 10.2 years) were referred from inpatient or outpatient clinics after onset of a manic, mixed, or depressed episode. FFT consisted of 21 sessions of psychoeducation, communication training, and problem-solving skills training. Crisis management consisted of 2 sessions of family education plus crisis intervention sessions as needed. Both protocols lasted 9 months. Patients received pharmacotherapy for 2 study years. Main outcome measures included time to relapse, depressive and manic symptoms, and medication adherence. RESULTS: Rates of study completion did not differ across the FFT (22/31, 71%) and CM groups (43/70, 61%). Patients undergoing FFT had fewer relapses (11/31, 35%) and longer survival intervals (mean +/- SD, 73.5 +/- 28.8 weeks) than patients undergoing CM (38/70, 54%; mean +/- SD, 53.2 +/- 39.6 weeks; hazard ratio, 0.38; 95% confidence interval, 0.20-0.75; P =.003; intent to treat). Patients undergoing FFT showed greater reductions in mood disorder symptoms and better medication adherence during the 2 years than patients undergoing CM. CONCLUSION: Combining family psychoeducation with pharmacotherapy enhances the postepisode symptomatic adjustment and drug adherence of bipolar patients.
RCT Entities:
BACKGROUND:Bipolarpatients are at risk for relapses of their illness even when undergoing optimal pharmacotherapy. This study was performed to determine whether combining family-focused therapy (FFT) with pharmacotherapy during a postepisode interval enhances patients' mood stability during maintenance treatment. METHODS: In a randomized controlled trial, 101 bipolarpatients were assigned to FFT and pharmacotherapy or a less intensive crisis management (CM) intervention and pharmacotherapy. Outcome assessments were conducted every 3 to 6 months for 2 years. Participants (mean +/- SD age, 35.6 +/- 10.2 years) were referred from inpatient or outpatient clinics after onset of a manic, mixed, or depressed episode. FFT consisted of 21 sessions of psychoeducation, communication training, and problem-solving skills training. Crisis management consisted of 2 sessions of family education plus crisis intervention sessions as needed. Both protocols lasted 9 months. Patients received pharmacotherapy for 2 study years. Main outcome measures included time to relapse, depressive and manic symptoms, and medication adherence. RESULTS: Rates of study completion did not differ across the FFT (22/31, 71%) and CM groups (43/70, 61%). Patients undergoing FFT had fewer relapses (11/31, 35%) and longer survival intervals (mean +/- SD, 73.5 +/- 28.8 weeks) than patients undergoing CM (38/70, 54%; mean +/- SD, 53.2 +/- 39.6 weeks; hazard ratio, 0.38; 95% confidence interval, 0.20-0.75; P =.003; intent to treat). Patients undergoing FFT showed greater reductions in mood disorder symptoms and better medication adherence during the 2 years than patients undergoing CM. CONCLUSION: Combining family psychoeducation with pharmacotherapy enhances the postepisode symptomatic adjustment and drug adherence of bipolarpatients.
Authors: David J Miklowitz; Christopher D Schneck; Patricia D Walshaw; Amy S Garrett; Manpreet K Singh; Catherine A Sugar; Kiki D Chang Journal: Early Interv Psychiatry Date: 2017-08-04 Impact factor: 2.732
Authors: Daniel P Dickstein; Kenneth E Towbin; Jan Willem Van Der Veen; Brendan A Rich; Melissa A Brotman; Lisa Knopf; Laura Onelio; Daniel S Pine; Ellen Leibenluft Journal: J Child Adolesc Psychopharmacol Date: 2009-02 Impact factor: 2.576
Authors: David J Miklowitz; Elizabeth L George; David A Axelson; Eunice Y Kim; Boris Birmaher; Christopher Schneck; Carol Beresford; W Edward Craighead; David A Brent Journal: J Affect Disord Date: 2004-10 Impact factor: 4.839
Authors: Louisa G Sylvia; Stephanie Salcedo; Amy T Peters; Pedro Vieira da Silva Magalhães; Ellen Frank; David J Miklowitz; Michael W Otto; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach Journal: J Nerv Ment Dis Date: 2017-03 Impact factor: 2.254
Authors: Daniel P Dickstein; Brendan A Rich; Roxann Roberson-Nay; Lisa Berghorst; Deborah Vinton; Daniel S Pine; Ellen Leibenluft Journal: Bipolar Disord Date: 2007-11 Impact factor: 6.744